MedTrace Logo

Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

NCT00644280 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2022-08-02

Study results available
· View outcomes & findings →

Summary

To determine whether ranibizumab therapy before and after tube insertion for glaucoma surgeries can maintain the patency of the tube and prevent scar formation, and increase the chances for a successful procedure compared to observation.

Conditions

Interventions

DRUG

Ranibizumab

intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections

Sponsors & Collaborators

Principal Investigators

  • Robert Bhisitkul, M.D., Ph.D. · University of California, San Francisco

  • Rajen U Desai · Stanford University

  • Patricia Tam · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2010-12-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00644280 on ClinicalTrials.gov